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cells. Altogether, we demonstrate that HSPB1 mutations 
induce hyperphosphorylation of NFs through Cdk5 and 
reduce anterograde transport of NFs.
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Introduction
Charcot–Marie–Tooth disease (CMT) is the most com-
mon inherited neurodegenerative disorder of the peripheral 
nervous system. CMT neuropathy is clinically and geneti-
cally heterogeneous, caused by mutations in a large num-
ber of genes with diverse functions. The genes associated 
with CMT disease may have a specific role in Schwann 
cells or in the peripheral neurons. Although some genes are 
expressed in every tissue and cell, the CMT-causing muta-
tions selectively affect peripheral nerves [46].
Missense mutations in the small heat shock protein 
HSPB1 (HSP27) are causative of axonal CMT type 2F 
(CMT2F) and distal hereditary motor neuropathy (HMN) 
[26]. The HSPB1 protein is ubiquitously expressed and 
belongs to the family of highly conserved ATP-independent 
molecular chaperones [28, 34]. We recently reported that 
some HSPB1 mutations show a higher chaperone activity 
than the wild-type protein, affect microtubule dynamics 
and impede axonal transport [5, 7, 22]. However, the pleio-
tropic nature of the HSPB1 protein suggests that some neu-
ron-specific functions could contribute to peripheral neu-
ropathy. Indeed, CMT-causing mutations in HSPB1 have 
been shown to cause aggregation of the neurofilament light 
protein, and therefore disruption of the neurofilament (NF) 
network [26, 74].
Abstract Mutations in the small heat shock protein 
HSPB1 (HSP27) are a cause of axonal Charcot–Marie–
Tooth neuropathy (CMT2F) and distal hereditary motor 
neuropathy. To better understand the effect of mutations in 
HSPB1 on the neuronal cytoskeleton, we stably transduced 
neuronal cells with wild-type and mutant HSPB1 and 
investigated axonal transport of neurofilaments (NFs). We 
observed that mutant HSPB1 affected the binding of NFs 
to the anterograde motor protein kinesin, reducing antero-
grade transport of NFs. These deficits were associated with 
an increased phosphorylation of NFs and cyclin-dependent 
kinase Cdk5. As Cdk5 mediates NF phosphorylation, inhi-
bition of Cdk5/p35 restored NF phosphorylation level, as 
well as NF binding to kinesin in mutant HSPB1 neuronal 
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Neurofilament light (NFL), together with neurofila-
ment medium (NFM), neurofilament heavy (NFH) and 
α-internexin, are neuron-specific proteins that form the main 
cytoskeletal elements in mature neurons [73]. As their high-
est concentration is found along the axon, disruption of the 
NF network may underlie degeneration of peripheral nerves. 
Moreover, NFs in axons are extensively phosphorylated. 
Phosphorylation of their C-terminal domains modulates their 
structural dynamics and function [17, 59] and is mainly regu-
lated by the interplay of five proline-directed kinases: p42/44 
mitogen-activated protein kinase (ERK1/2 MAPK), p38 
MAPK, c-jun-N terminal kinase (JNK), glycogen synthetase 
kinase 3 (GSK3) and cyclin-dependent kinase 5 (Cdk5) [3, 
57, 65]. Each kinase can phosphorylate distinct lysine–ser-
ine–proline (KSP) motifs in the C-terminal domains of NFM 
and NFH, suggesting their ability to differentially affect the 
functioning of NFs [2, 16]. Here, we studied the effect of 
mutant HSPB1 on NF dynamics and phosphorylation.
Materials and methods
Cell lines and DNA constructs
Human neuroblastoma cells (SH-SY5Y) were cultured in 
minimum essential medium (Life Technologies, Ledeberg, 
Belgium) supplemented with 10 % fetal calf serum, 1 % non-
essential amino acids (Life Technologies) and 1 % glutamine 
(Life Technologies) and incubated at 37 °C in a humidified 
atmosphere (5 % CO2). Stable SH-SY5Y cell lines were 
generated by lentiviral transduction [48] using constructs 
encoding wild-type (WT) or mutant [Arg127Trp (R127W), 
Ser135Phe (S135F) and Pro182Leu (P182L)] HSPB1 as 
previously described [5]. The PAGFP-NFM construct was 
a generous gift from Prof. Dr. Anthony Brown (Department 
of Neuroscience, Ohio State University, Columbus, USA) 
[20]. Cells co-expressing HSPB1-WT and PAGFP-NFM, or 
HSPB1-P182L and PAGFP-NFM, or PAGFP-NFM alone, 
were generated for live cell imaging experiments.
Knockdown of Cdk5 was performed with MISSION® 
shRNA Cdk5 constructs (Sigma, Bornem, Belgium). The 
shRNA constructs were sh3 (TRCN0000195513), sh4 (TRCN 
0000194974), sh5 (TRCN0000021465), sh6 (TRCN 
0000021466) and sh7 (TRCN0000021467). The efficiency 
of these constructs was verified and the level of Cdk5 
knockdown determined by Western blotting (WB) (data not 
shown). One construct (sh3) was selected to create double 
stable cell lines with the HSPB1 WT and mutant constructs.
Antibodies and inhibitors
We used the following antibodies: anti-HSPB1 (Enzo 
Life Sciences, Antwerpen, Belgium), anti-NFL DA2 
(Cell Signaling, Danvers, MA, USA), anti-actin (Sigma), 
anti-Cdk5 DC17 (Santa Cruz, Heidelberg, Germany), 
anti-phosphorylated NFs SMI34 (Abcam, Cambridge, 
UK), anti-kinesin heavy chain antibody KN-01 (ab9097) 
(Abcam), anti-NFM NF-09 (Abcam), anti-phophoY15-
Cdk5 (Abcam), anti-phosphorylated NFs SMI-31 (Euro-
gentec, Seraing, Belgium), anti-non-phosphorylated NFs 
SMI-33 (Eurogentec), anti-NFH SMI32 (Eurogentec), 
anti-APP (Sigma), goat anti-mouse IgG1-HRP (Southern-
Biotech, Birmingham, Alabama, USA), goat anti-mouse 
IgG2a-HRP, goat anti-mouse IgG2b-HRP (SouthernBio-
tech), peroxidase-conjugated goat anti-mouse IgG (Jackson 
Laboratories Inc., Bar Harbor, Maine, USA), peroxidase-
conjugated goat anti-rabbit IgG (Jackson Laboratories 
Inc.), anti-V5 (Life Technologies), Alexa Fluor® 488 goat 
anti-mouse IgG (Life Technologies) and Alexa Fluor® 594 
goat anti-mouse IgG (Life Technologies).
The specificity of the antibodies against phosphorylated 
and non-phosphorylated NFs was verified using cell lysates 
treated with or without phosphatase inhibitor or arctic 
phosphatase. The SMI-31 antibody is directed against the 
phophorylated KSP repeats in the C-tail of NFH and to a 
lesser extent NFM, while the SMI-33 antibody is described 
to detect non-phosphorylated NFH and to a lesser extent 
NFM [49, 53, 60]. The arctic phosphatase treatment 
dephosphorylated NFH as indicated by a shift in electro-
phoretic mobility on the agarose gel [57]. As expected, the 
SMI-31 antibody did not probe NFH or NFM after treat-
ment with arctic phosphatase, while the SMI-33 antibody 
still probed NFH and NFM after arctic phosphatase treat-
ment (data not shown). The phosphorylation status of the 
NFs was therefore assessed with the SMI-31 antibody. The 
SMI-34 antibody was used to detect the phosphorylated 
S/TPXH/K/R repeat motif in the C-domains of NFH and 
NFM, specifically phosphorylated by Cdk5/p35 [9].
As inhibitors we used: SB203580 (p38 inhibitor, Enzo 
Life Technologies), SP600125 (JNK inhibitor, Enzo Life 
Technologies), U0126 (MEK1/2 inhibitor, Cell Signaling), 
TDZD-8 (GSK3β inhibitor, Sigma) and roscovitine (Cdk5 
inhibitor, Cell Signaling). Specific kinase inhibitors were 
diluted to 10 μM directly in medium and cells were incu-
bated for 16–24 h. Efficiency of all inhibitors was verified 
by WB by assessing the phosphorylation level of the kinase 
itself or a known downstream substrate unrelated to NFs 
(data not shown).
Neuronal differentiation of SH-SY5Y cells with retinoic 
acid
The protocol was adapted from Ammer and Schulz, 1994 
[8, 25]. Glass Bottom Culture Dishes (35 mm, thick-
ness 1.5, 14 mm) (further referred to as ‘imaging dishes’) 
or 12-well plates were coated overnight with 0.1 mg/ml 
95Acta Neuropathol (2013) 126:93–108 
1 3
poly-l-ornithine (Sigma) at room temperature. Cells were 
seeded at a density of 10.000/cm2 in medium with 1 % 
non-essential amino acids, 1 % glutamine, 2 % fetal calf 
serum and 10 μM retinoic acid (Sigma). Differentiation 
was performed in Neurobasal A medium (Life Technolo-
gies) containing 2 % B27 supplement (Life Technologies), 
1 % glutamine and 20 μM retinoic acid. The medium was 
refreshed every other day. After 7 days of differentiation, 
cells were imaged, collected for WB or fixed in 4 % para-
formaldehyde for immunocytochemistry.
Western blotting
Unless otherwise indicated, cells were lysed in E1A lysis 
buffer [20 mM HEPES (pH 7.9) with 1 % (vol/vol) NP-40, 
250 mM NaCl, 1 mM EDTA, 20 mM β-glycerophosphate, 
10 mM NaF, 1 mM Na3OVO4, 2 mM DTT] and Complete 
protease inhibitor mixture (Roche Applied Technologies, 
Vilvoorde, Belgium). Cells were sonicated for 10–30 s 
on ice using the U50-control sonicator (IkaLabortechnik, 
Staufen, Germany) and subsequently incubated for 30 min 
on ice. Protein concentrations were measured using the 
Bradford protein assay (Bio-Rad, Nazareth, Belgium) and 
equal amounts of protein extract were prepared for SDS-
PAGE by addition of SDS-PAGE sample buffer and heat-
ing the samples at 95 °C for 10 min. Proteins were sepa-
rated on NuPAGE gels (Life Technologies) and transferred 
to a nitrocellulose membrane (Hybond™-P, Amersham/
Pharmacia) using the wet blotting method. After blocking 
in 5 % milk powder in PBS or TBS, supplemented with 
0.1 % (vol/vol) Tween-20, blots were incubated with a pri-
mary antibody overnight at 4 °C and 1 h with a secondary 
horseradish peroxidase-conjugated antibody. Blots were 
developed using the enhanced chemiluminescence Plus™ 
detection system (GE healthcare, Diegem, Belgium). In all 
experiments, except Triton-X 100 experiments, actin was 
used as loading control.
Band intensity was determined by quantifying the ‘mean 
pixel gray’ values using ImageJ software (http://rsbweb.nih.
gov/ij/) after Gaussian blur and background subtraction 
on the inverted image. The ‘mean pixel gray’ values were 
measured in a rectangular region of interest. Band inten-
sities were normalized to β-actin levels by dividing the 
‘mean pixel gray’ values of the band of interest by the actin 
‘mean pixel gray’ values. Data from multiple experiments 
are presented as relative quantities by normalizing to the 
non-transduced control.
Immunocytochemistry and immunofluorescence 
microscopy
Immunostaining was performed according to standard pro-
tocol. Briefly, cells were fixed in 4 % paraformaldehyde 
for 30 min and permeabilized with 0.1 % (vol/vol) Triton-
X 100 in phosphate-buffered saline (PBS). Blocking was 
done with 5 % goat serum (Dako, Heverlee, Belgium) for 
1 h, primary antibodies were incubated for 1 h and second-
ary antibodies for 30 min at room temperature. Nucleus 
staining was done with Hoechst33342 (Invitrogen), after 
which cells were mounted with Dako fluorescent mount-
ing medium (Dako) and examined with an Axiovert200 
fluorescence microscope, equipped with a CCD Axiocam 
camera and Axiovision software (Carl Zeiss, Zaventem, 
Belgium). Images were acquired with a 63× Plan-
Apochromat objective (1.4NA) and standard fluorescence 
filters.
Laser scanning confocal microscopy of immunostained 
samples was performed on a Zeiss LSM700 microscope 
equipped with a 63× Plan-Apochromat objective (1.4 NA). 
Image stacks (sampled at Nyquist resolution in XY and Z) 
were deconvolved using the ImageJ Iterative Deconvolve 
3D plugin with theoretically calculated point spread func-
tion, created with the ImageJ Diffraction PSF CD plugin.
Superresolution structured illumination microscopy was 
performed on a Zeiss ELYRA S.1 microscope equipped 
with a 63× Plan-Apochromat objective (1.4 NA).
Quantification of the number of V5-positive, or NF-
aggregate positive cells was performed manually by 
counting a minimum of 100 cells per experiment for 
each cell line. Cells were scored visually. For quantifica-
tion of the mean fluorescence intensity, image fields were 
selected at random in the transmitted light mode, without 
exposure to the fluorescence excitation light. All images 
were captured with the same exposure time. In the soma 
or in neurites of respectively undifferentiated or differen-
tiated SHSY-5Y cells, fluorescence intensity was quanti-
fied by measuring the ‘mean pixel gray’ value in a region 
with the same dimensions using ImageJ. All quantifica-
tions were performed blind for the treatment conditions 
and in triplicate.
Axonal transport studies with PAGFP-NFM
Cells were seeded in an imaging dish and differenti-
ated as explained above. The medium was changed right 
before imaging. All genotypes were imaged on the same 
day, during 7 days, for which three different differentia-
tions were performed. Image time series were acquired 
on a Zeiss LSM700 inverted confocal laser scanning 
microscope equipped with temperature and CO2 incuba-
tion. Imaging conditions and microscope settings were 
identical for all time series. Using a Plan-Apochromat 
63×/1.4NA objective and laser light excitation at 1 % 
transmission of a 10 mW 488 nm diode laser, 512 × 512 
images were acquired with a pixel dwell time of 3.15 μs 
and pixel size of 0.198 μm. Image fields containing 
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several neurites were selected in transmitted light mode 
and, for photoactivation, a region of interest containing a 
15 μm long neuritic segment was drawn in the Zeiss Zen 
2009 software. Every time series consisted of (1) two pre-
photoactivation frames, (2) the photoactivation phase (2 
iterations using the 5 mW 405 nm laser at 100 % trans-
mission) and (3) 147 frames at 10.1 s time intervals. To 
specifically assess the directionality of movement, we 
counted the number of photoactivated neurofilaments 
that could unambiguously be discriminated as individual 
filaments that moved out of the photoactivated zone either 
anterogradely or retrogradely at high speed. To quanti-
tatively assess movement of NFs in general, the leading 
edges of filaments moving out of the photoactivated neu-
ritic segment were tracked by using the Manual Tracking 
plugin of ImageJ and by using the cell body as a reference 
point. The XY-coordinates of the filament tracks, origi-
nating from the ImageJ output file, were used to analyze 
the tracks in a custom-made script in R (http://www.r-
project.org/). Briefly, the displacement of the leading edge 
between two consecutive frames was used to calculate the 
speed and directionality at each time point. A filament 
was considered in pause if the calculated speed was below 
0.06 μm/s; this represents a displacement of three pixels 
during two consecutive time frames that we considered as 
the precision limit of our analysis. This value is consist-
ent with earlier reports on analysis of NF movement [67]. 
These raw parameters were used to classify the speeds 
into different categories and to extract several parameters 
that describe the movement pattern. For the data that is 
presented, the mean parameters were calculated for each 
NF track, which was used to calculate the average and 
SEM for each genotype. In total, more than 120 time 
series, consisting of more than 600 tracks and 40,000 time 
points, were analyzed.
Co-immunoprecipitation
Cells were lysed in NP-40 buffer (PBS, 0.5 % (vol/vol) 
Nonidet P-40, 20 mM β-glycerophosphate, 10 mM NaF, 
1 mM Na3OVO, 2 mM DTT) and Complete protease 
inhibitor mixture (Roche Applied Science) and left on ice 
for 30 min [50, 69, 70, 72]. We considered the insolubil-
ity of the NF proteins and therefore worked with total cell 
lysates. No harsh detergent was added to the lysates before 
IP. Protein measurement was performed to equalize protein 
concentration from different cell lines before immunopre-
cipitation (IP). Sepharose 6B (Sigma-Aldrich) and protein 
G beads (GE Healthcare) were used and the anti-SMI-31 
antibody was incubated overnight at 4 °C, after which the 
beads were pulled down by centrifugation. The beads were 
repeatedly washed before preparing SDS-polyacrylamide 
electrophoreses.
Preparation of Triton-X 100-soluble/-insoluble fractions
Cells were lysed in a 1 % Triton-X 100 buffer (50 mMTris 
(pH 6.8) with 1 % (vol/vol) Triton-X 100, 5 mM 
EDTA, 50 μg/ml leupeptin, 1 mM Na3OVO4, 20 mM 
β-glycerophosphate, 10 mM NaF) and Complete protease 
inhibitor mixture (Roche Applied Science), by pipetting up 
and down and leaving them on ice for 20 min. After cen-
trifugation at 15,000×g for 20 min at 4 °C, the superna-
tant was collected as ‘Triton-X 100-soluble fraction’ and 
the pellet fraction (‘Triton-X 100-insoluble fraction’) was 
resuspended in E1A lysis buffer and sonicated for 30 s. On 
both fractions, protein concentrations were measured and 
equal concentrations were subjected to WB. The amyloid 
precursor protein (APP) was used as a positive control to 
determine if the experiment was accurately executed, as it 
is supposed to be Triton-X 100 soluble.
Transmission electron microscopy
Cells were grown on poly-l-ornithine-coated eight-well 
chambered Permanox slides (Nunc, Lab-Tek) and treated 
for neuronal differentiation as described above. Cells 
were fixed in 0.1 M sodium cacodylate-buffered (pH 7.4) 
2.5 % glutaraldehyde solution for 2 h at 4 °C. After rins-
ing (3 × 10 min) in 0.1 M sodium cacodylate-buffered (pH 
7.4), 7.5 % saccharose, they were post-fixed in 1 % OsO4 
solution for 1 h. After dehydration in an ethanol gradient 
(70 % ethanol for 20 min, 96 % ethanol during 20 min, 
100 % ethanol for 2 × 20 min), cells were embedded in 
EM-bed812. Ultrathin sections were stained with uranyl 
acetate and lead citrate, and examined in a Tecnai G2 Spirit 
Bio Twin Microscope (FEI, Eindhoven, The Netherlands) 
at 100 kV.
Statistical analysis
For all experiments, results are shown as average ± stand-
ard error of the mean (SEM). GraphPad Prism 5 software 
was used for statistical calculations. One-way ANOVA 
with post hoc Bonferroni’s multiple comparison test was 
used for statistical analysis; p values are indicated.
Results
Mutation in HSPB1 reduces anterograde axonal transport 
of neurofilaments
To test if mutations in HSPB1 affect axonal transport of 
NFs, we performed live cell imaging of axonal segments 
of wild-type (WT) and mutant HSPB1 cells expressing 
NFM coupled to a photoactivatable GFP (PAGFP-NFM) 
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[20]. This method allowed us to visualize the photoacti-
vated fluorescent filaments moving into non-photoactivated 
axonal regions (Fig. 1a). We used human neuroblastoma 
cells (SH-SY5Y) because these cells express all NF subu-
nits endogenously. The SH-SY5Y cells were transduced 
with lentiviral vectors containing WT or mutant HSPB1 
as described in “Materials and methods”. When cells 
expressed only PAGFP-NFM or PAGFP-NFM and WT 
HSPB1, the majority of filaments moved anterogradely, 
whereas cells expressing PAGFP-NFM and mutant 
HSPB1-P182L showed a higher frequency of filaments 
moving retrogradely, and a lower frequency of filaments 
moving anterogradely (Fig. 1b). To determine whether this 
effect was a consequence of a decrease in axonal transport 
rates, we compared the speed at which NFs were trans-
ported in cells expressing WT and mutant HSPB1. The NF 
axonal transport velocity results from rapid anterograde or 
retrograde movements interrupted by long periods of pause 
Fig. 1  Neurofilaments move 
less in the anterograde direc-
tion and bind less to kinesin in 
mutant HSPB1 SH-SY5Y cells. 
a Live cell imaging experi-
ments showing the movement 
of PAGFP-NFM. The first 
frame is an image of an axonal 
neurite before photoactivation 
of PAGFP-NFM. The second 
frame shows an image of the 
photoactivated zone (indicated 
by open arrowheads). The fol-
lowing frames show photoacti-
vated filaments that moved out 
of the photoactivated zone. Pic-
tures are taken 30 to 200 s after 
the photoactivation (the arrow 
and the full arrowhead indicate 
two separate moving filaments). 
b Quantification of the amount 
of filaments moving out of the 
activated zone in anterograde 
and retrograde direction (per 
hour), indicating a shift in the 
direction of NF movement in 
mutant (P182L) HSPB1 cells. 
c Co-IP showing the interac-
tion between phosphorylated 
NFs and kinesin. Phospho-NFs 
were immunoprecipated with 
the SMI-31 antibody. d Rela-
tive quantification of the co-IP 
experiments shown in c, by 
calculating the ratio of kinesin 
in the IP over phosphoryl-
ated NFs. NT non-transduced 
cells; *p < 0.05; **p < 0.01; 
***p < 0.001; n = 3
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[47, 67]. We therefore evaluated NF movement velocity, 
pausing frequency and the frequency of switches made 
between retrograde and anterograde movements, but could 
not observe any statistical difference between cells express-
ing the different HSPB1 constructs (Table 1). We conclude 
that mutant HSPB1 decreases the frequency of anterograde 
transport of NFs in favor of retrograde transport.
Mutation in HSPB1 decreases neurofilament binding to 
kinesin
Anterograde transport of NFs along the axon is mediated 
by the motor protein kinesin, while dynein allows both 
anterograde and retrograde transport [64]. To determine 
whether the altered axonal transport in mutant HSPB1 
SH-SY5Y cells is caused by a deficit in the interaction 
between NFs and their motor proteins, we co-immuno-
precipitated (co-IP) phosphorylated NFs and kinesin or 
p150glued, a component of the dynactin–dynein complex 
[17, 49]. We used the SMI-31 antibody that recognizes 
phosphorylated NFs that are able to interact with kinesin 
[66]. The SMI-31 antibody usually detects four separate 
signals in the SH-SY5Y cells, of which the upper three 
bands probably correspond to different phospho-forms 
of NFH and the single lower band corresponds to phos-
pho-NFM. The interaction between NFs and kinesin was 
significantly reduced in all cell lines expressing a mutant 
HSPB1 construct (Fig. 1c, d). In contrast, HSPB1 muta-
tions did not affect NF binding to p150glued (Supple-
mentary Fig. 1). These results suggest that mutant HSPB1 
may affect axonal transport of NF by altering the NFs–
kinesin interaction.
Mutation in HSPB1 increases NF–NF interaction
The axonal transport of neurofilaments is mediated by 
continued shuttling between mobile and stationary states 
(reviewed in [29]). In the stationary phase, bundles of 
NFs are closely apposed, phosphorylated NFs that gained 
higher binding affinity for each other [17, 19]. Hence, 
the decreased interaction between the NFs and kinesin, 
observed in cells with mutant HSPB1, is likely to coincide 
with an increase in NF bundling. Therefore, we compared 
NF–NF interactions in cells expressing WT and mutant 
HSPB1. By co-IP we observed an increased interaction 
between the NFs in mutant HSPB1 cell lines compared to 
non-transduced or HSPB1-WT controls (Fig. 2a–d).
As NF bundles form polymers that are insoluble com-
pared to their monomeric counterparts, we assessed NF 
solubility using the Triton-X 100 detergent. In cells stably 
expressing mutant HSPB1-S135F and HSPB1-P182L, the 
phosphorylated NFs were more retained in the insoluble 
pellet fraction compared to control cells (Fig. 3a–b), sug-
gesting that NFs could be trapped in NF bundles or aggre-
gates. We tested this hypothesis by analyzing NF morphol-
ogy in the different cell lines by staining for NFH, often 
used as a neuronal marker (Fig. 4a). However, we could 
detect neither NF-positive aggregates nor any signifi-
cant morphological differences between WT and mutant 
HSPB1 expressing cells. The NFs were present in a fila-
mentous network independently of the evaluated HSPB1 
genotype, and no differences in NF bundling were detected 
(Fig. 4b–c). To evaluate the intermediate filaments at the 
ultrastructural level, we next performed transmission elec-
tron microscopy on the axonal neurites of the SH-SY5Y 
cells. However, we were unable to detect differences in the 
intermediate filament distribution between WT and mutant 
HSPB1 cells (Fig. 4d).
Mutant HSPB1 increases neurofilament phosphorylation
Thus far, we have demonstrated that in SH-SY5Y cell lines 
transduced with CMT-associated HSPB1 mutants, NFs 
undergo less anterograde transport and interact less with 
kinesin, but bind more to each other. Interestingly, each of 
these properties can be regulated by the same event: phos-
phorylation of the large NF subunits [1, 70, 71]. Through 
the numerous KSP repeat motifs in their long C-terminal 
tail domain, NFH and NFM can be highly phosphoryl-
ated and play a crucial role in NFs properties [32, 59]. 
We investigated the phosphorylation status of NFs in SH-
SY5Y cells expressing WT or mutant HSPB1 using the 
SMI-31 antibody. When cells were transduced with mutant 
forms of HSPB1, the level of phosphorylated neurofila-
ment was slightly but significantly increased (Fig. 5a–b). 
The same effects were observed when cells were subjected 
Table 1  Parameters of NF axonal transport, measured through live 
cell imaging with a PAGFP-NFM construct
Data are represented as mean ± SEM. Pause was defined as speed 
rates between −0.06 and 0.06 μm/s. To determine “mean velocity” 
and “mean velocity per second”, anterograde and retrograde param-
eters were grouped, neglecting transport direction. Switches are 
defined as changes in directionality of the movement
** p < 0.01
PAGFP-NFM HSPB1-WT HSPB1-P182L




0.099 ± 0.007 0.095 ± 0.008 0.091 ± 0.006




0.166 ± 0.011 0.162 ± 0.013 0.164 ± 0.011
Frequency of  
directionality 
switches (s−1)
0.021 ± 0.001 0.020 ± 0.002 0.021 ± 0.001
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to neuronal differentiation with retinoic acid (Fig. 5e, f). 
Subsequently, the undifferentiated and differentiated SH-
SY5Y cell lines were immunostained for phosphorylated 
NFs, and quantification of the mean fluorescence inten-
sity confirmed the significant increase in phosphorylated 
NFs in the mutant HSPB1-S135F and HSPB1-P182L cell 
Fig. 2  Neurofilaments in 
mutant HSPB1 cell lines bind 
more to each other and to Cdk5. 
a Co-IP experiment showing 
the interaction patterns between 
the NFs in the different cell 
lines, after immunoprecipitating 
phospho-NFs with the SMI-31 
antibody. b–e Relative quantifi-
cation of the co-IP experiments 
with specific antibodies against 
NFH (b), NFM (c), NFL (d) 
and Cdk5 (e). NT non-trans-
duced cells; *p < 0.05; n = 3
Fig. 3  Neurofilaments in 
mutant HSPB1 cell lines are 
more Triton-X 100 insoluble. 
a Western blot of Triton-X 
100-soluble and -insoluble 
fractions of mutant HSPB1 and 
controls cells. APP was used as 
Triton-X 100-soluble positive 
control. b Quantitative analysis 
of the Triton-X 100 experiments 
shown in a. The ratio insoluble/
soluble fractions was calculated 
for each cell line and for each 
NF specific antibody, but is 
only depicted for the SMI-31 
antibody. NT non-transduced 
cells; *p < 0.05; n = 3
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lines (Fig. 5d–g). It is important to note that the transduc-
tion of cells with an HSPB1 construct (WT or mutant) 
increased the expression of the NFs, compared to non-
transduced control cells. We observed a positive correlation 
between the protein expression levels of HSPB1 and non-
phosphorylated NFs (Pearson correlation for linear meas-
ures: R = 0.6084; p value: 0.0358; n = 12). This increase 
reflects a more general effect of HSPB1 on the expression 
level of the NFs. However, when calculating the ratio of 
phosphorylated versus non-phosphorylated NFs, we found 
that the increase in phospho-NFs was independent of the 
increase in non-phosphorylated NFs (Fig. 5c). There was 
no positive correlation between the protein expression level 
of HSPB1 and phosphorylated NFs. We therefore conclude 
that mutant HSPB1 induces an increase in phospho-NFs 
and this increase is not attributable to HSPB1 levels.
Fig. 4  Mutant HSPB1 does not affect neurofilament network for-
mation or neurofilament bundling. No differences in the organiza-
tion or bundling of the NF network were observed in SH-SY5Y cells 
stably expressing WT or mutant HSPB1 construct, by using differ-
ent microscopy techniques. a–c Cells immunostained for NFH were 
imaged with confocal laser scanning microscopy followed by 3D 
iterative deconvolution (a, b) and by superresolution structured illu-
mination microscopy (c). d At the ultrastructural level, no differences 
in intermediate filament distribution could be observed between the 
cells expressing the different constructs, by using transmission elec-
tron microscopy. No clear occurrence of NF bundles was present after 
evaluating at least 30 neurites per genotype. The scale bar is 10 μm 
in a–c and 100 nm in d. NT non-transduced cells; arrowheads micro-
tubules, arrows intermediate filaments
101Acta Neuropathol (2013) 126:93–108 
1 3
Increased NF phosphorylation in HSPB1 mutant cells  
is mediated by Cdk5
Because of the observed effects of mutant HSPB1 on the 
phosphorylation of NFs, we searched for the protein kinase 
responsible for the increased NF phosphorylation in mutant 
HSPB1 cells. Five proline-directed kinases have previously 
been shown to be able to phosphorylate the KSP repeat 
motifs in the C-tail domains of NFM and NFH: ERK1/2, 
p38, JNK, GSK3β and Cdk5 [3, 9, 15, 65]. Here, we selec-
tively inhibited the activity of these five kinases and found 
that only roscovitine, a Cdk5/p35 inhibitor, prevented NF 
hyperphosphorylation in mutant HSPB1 cell lines. The data 
for roscovitine is shown in Fig. 6a, b. We confirmed these 
results in a second experiment where Cdk5 was silenced 
using a specific shRNA construct (sh3) that knocked down 
the expression of Cdk5 to 20 % in WT and mutant HSPB1 
cell lines (Fig. 6c–e).
Fig. 5  Mutant HSPB1 cell lines show hyperphosphorylated neu-
rofilaments. a Western blot experiment showing phosphorylated 
(SMI-31) and non-phosphorylated NFs (SMI-33) from SH-SY5Y 
cells stably transduced with HSPB1. b Relative quantification of 
the phosphorylated NF signal intensities of HSPB1 transduced and 
non-transduced (NT) cells (n = 3). c Ratio of phospho- versus non-
phospho-NFs after quantification of the relative band intensities. 
d Mean fluorescent intensity after immunostaining of phosphoryl-
ated NF on non-differentiated SH-SY5Y cells [non-transduced 
(number of cells = 179), HSPB1-WT (n = 234), HSPB1-R127W 
(n = 173), HSPB1-S135F (n = 204) and HSPB1-P182L (n = 220) 
from 4 independent experiments]. e Western blot experiment show-
ing phospho-NFs and non-phoshorylated NFs in differentiated 
SH-SY5Y cells. The anti-V5 antibody shows the expression of the 
HSPB1-V5 constructs. f Relative quantification of the phosphoryl-
ated NF signal intensities after neuronal differentiation with retinoic 
acid (n = 2). g Quantification of the mean fluorescent intensity of 
phosphorylated NF in differentiated SH-SY5Y cells [non-transduced 
(n = 122), HSPB1-WT (n = 134), HSPB1-R127W (n = 143), 
HSPB1-S135F (n = 131) and HSPB1-P182L (n = 136) from 3 
independent experiments). NT non-transduced cells; *p < 0.05; 
**p < 0.01; ***p < 0.001
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Two major phosphorylation sites in Cdk5 have been 
shown to regulate its activity. Phosphorylation of Thr14 
inhibits the activity of Cdk5, while phosphorylation of 
Tyr15 increases its activity [23]. To determine whether 
HSPB1 mutations could affect Cdk5 activity, we com-
pared Cdk5 phosphorylation in WT and mutant HSPB1 
cell lines. We found an increased phosphorylation of Cdk5 
at the Tyr15 site in mutant HSPB1 cell lines (S135F and 
P182L), compared to controls (Fig. 7a–b), while the level 
of the Cdk5 protein was unaltered (Fig. 7c). We conclude 
that Cdk5 activity is increased in HSPB1 mutants.
To further assess the role of the increased Cdk5 activ-
ity, we compared the interaction of Cdk5 with the NFs 
in WT and mutant HSPB1 cells. Accordingly, our results 
showed an increased binding of Cdk5 to the phosphoryl-
ated NFs in protein extracts from the mutant HSPB1 cell 
lines (Fig. 2a, e). Furthermore, the HSPB1-S135F and 
P182L mutant cell lines displayed an increased phospho-
rylation of the S/TPXH/K/R repeat motif in the C-domains 
of NFH and NFM, a site specifically targeted by Cdk5/p35, 
which can be detected by the SMI-34 antibody specifically 
(Fig. 7d–e). Together, these results suggest that increased 
phosphorylation of NFs in HSPB1 mutant neuronal cells is 
mediated by an increased activity of Cdk5.
Silencing of Cdk5 restores NF–kinesin interaction and NF 
solubility in HSPB1 mutants
To further assess the role of Cdk5 in mutant HSPB1 cell 
lines, we tested if silencing of Cdk5 with shRNA could 
prevent the atypical NF properties: decreased bind-
ing of NFs to kinesin, increased NF-Cdk5 interaction 
and increased NF solubility. As expected, when Cdk5 
was constitutively silenced, no difference in NF–Cdk5 
Fig. 6  Inhibition and specific 
knockdown of Cdk5 restore 
the NF phosphorylation status 
in mutant HSPB1 cell lines. 
a Western blot showing the 
NF phosphorylation in SH-
SY5Ycells incubated for 24 h 
with 10 μM roscovitine (Cdk5/
p35 inhibitor) or dimethyl 
sulfoxide (DMSO) as a control 
(n = 3). b Quantification of 
the band intensities of the 
experiment shown in a. The 
data were normalized against 
actin (n = 3). c Quantification 
of signal intensities to assess the 
residual protein level of Cdk5 in 
the Cdk5 knockdown cell line 
sh3 (n = 3). The percentage of 
Cdk5 protein was calculated 
with the non-transduced cells as 
control, as the signal intensity 
of the latter was set to 100 %.  
d Western blot experiment 
showing the NF phosphoryla-
tion in WT and mutant HSPB1 
cell lines, where Cdk5 was 
silenced by shRNA. The anti-
Cdk5 antibody shows the level 
of Cdk5 knockdown, whereas 
anti-V5 antibody shows the 
expression of the HSPB1-V5 
constructs. e Quantitative analy-
sis of the level of phospho-NF 
in WT and mutant HSPB1 cell 
lines, after Cdk5 silencing. NT 
non-transduced cells; *p < 0.05; 
***p < 0.001; n = 3
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interaction could be observed between WT and mutant 
Cdk5-silenced cells (Fig. 8a, c). Furthermore, silenc-
ing of Cdk5 also prevented the decreased binding of 
NFs with kinesin formerly seen in HSPB1 mutant cell 
lines (Fig. 8a, b). Additionally, no differences could be 
seen in NF solubility between WT and mutant cell lines 
(Fig. 8d, e). These experiments suggest that silencing 
Cdk5 can prevent the aberrant NF phenotype observed in 
cells expressing mutant HSPB1.
Discussion
In this study, we show that CMT-causing mutations in 
HSPB1 reduce the anterograde axonal transport of NFs, 
which might be a consequence of decreased affinity of 
NFs for the anterograde motor protein kinesin in mutant 
cell lines. We demonstrated that the impaired NF–kinesin 
binding is in part attributable to an increase in phosphoryla-
tion of KSP sites of NFs. Although NF hyperphosphoryl-
ation was subtle and transient, we showed that in mutant 
cell lines, NFs displayed known characteristics of hyper-
phosphorylation, as their insolubility and affinity toward 
each other were increased. Finally, we demonstrated that 
these effects were at least partially mediated by the proline-
directed kinase Cdk5.
Our results, showing that NF axonal transport is asso-
ciated with NF phosphorylation, are in line with previ-
ous studies [37, 41]. Our time lapse imaging showed that 
NFs underwent both anterograde and retrograde transport 
interrupted by pausing periods, as previously described 
[47, 67]. It is reported that 73–80 % of NFs are generally 
in pause [47, 67], while we observed only 54–59 % of the 
NFs pausing. However, with our imaging method only 
those NFs leaving the photoactivated zone (and pausing at 
some point) are monitored and not those that remain in the 
Fig. 7  Cdk5/p35 is more active 
in mutant HSPB1 cell lines.  
a Western blot showing the 
Tyr15 phosphorylation level of 
Cdk5 (P-Cdk5) in non-trans-
duced, WT and mutant HSPB1 
SH-SY5Y cells. The total Cdk5 
levels were detected with a non-
phospho-specific Cdk5 antibody 
(n = 3). b Relative quantifica-
tion of the phospho-Y15-Cdk5 
signals. c Relative quantification 
of the non-phospho-Cdk5 sig-
nals. d Western blot experiment 
showing the phosphorylation 
level of NFs recognized by the 
SMI34 antibody. e Relative 
band quantification of signal 
intensities for the SMI-34 
antibody shown in d. *p < 0.05; 
**p < 0.01; n = 3
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photoactivated zone, resulting in an apparent underestima-
tion of the NF pausing frequency.
Anterograde axonal transport of NFs is known to be 
mediated by kinesin [69] and we found that NF interac-
tion with kinesin is phospho-dependent, confirming several 
studies [33, 37, 41, 70]. Our results suggest that the affected 
anterograde axonal transport observed in our mutant cell 
lines might play a crucial role in the pathomechanisms of 
CMT neuropathy.
Our results strongly suggest a central role for NFH 
and NFM phosphorylation in the NF atypical properties 
observed in HSPB1 mutants. Our strongest evidence comes 
from the demonstration that knocking down Cdk5 prevents 
NF hyperphosphorylation and interaction with kinesin. 
Inhibition and knockdown of Cdk5/p35 did not completely 
prevent NF phosphorylation, suggesting the involvement of 
other proline-directed kinases. The increased NF phospho-
rylation in cells only expressing the Cdk5 shRNA construct 
suggests that some compensatory mechanism by other 
kinases known to phosphorylate NF [51] may take place. 
Further support for the role of Cdk5 in NF axonal transport 
has been shown in literature [54]. Our study suggests a con-
nection between the activity of Cdk5, NF hyperphosphoryl-
ation and the consequences on NF binding and dynamics 
Fig. 8  Specific knockdown of Cdk5 restores the interaction between 
phosphorylated neurofilaments and kinesin or Cdk5, and the neu-
rofilament insolubility in mutant HSPB1 cell lines. a Repetition 
of the co-IP SMI-31 experiment shown in Figs. 1c and 2a, but per-
formed with the sh3 double-transduced SH-SY5Y cell lines (n = 3). 
b–c Quantitative analysis of the co-IP experiment for kinesin (b) and 
Cdk5 (c). d Repetition of the Triton-X 100 experiment as shown in 
Fig. 3, but performed with the sh3 double-transduced SH-SY5Y cell 
lines. e Quantifications of the insoluble/soluble ratios of the Triton-X 
100 experiments as previously described (n = 3). **p < 0.01
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in mutant HSPB1 cells. However, the intermediates in 
this molecular cascade are missing. Although HSPB1 and 
Cdk5/p35 are not known to interact with each other, they 
are involved in many common pathways such as apoptosis, 
reorganization of the cytoskeleton, cell growth and differ-
entiation [35]. HSPB1 and Cdk5 have also been shown to 
be upregulated by Heat Shock Factor 2 [18, 27]. However, 
to our knowledge no direct or indirect interaction between 
the two proteins has been described. As HSPB1 is known 
to bind to the p38 mitogen-activated protein kinase [58], 
its indirect effect, through ERK1/2, on Cdk5 is a plausible 
hypothesis that is yet to be tested.
Although the three mutations studied here induce a 
decreased interaction between NFs and the motor protein 
kinesin, the NF–NF and NF–Cdk5 interactions were not 
significantly increased in the HSPB1-R127W mutant cells. 
This observation indicates that various mutations may dif-
ferentially affect HSPB1 structure and function. Indeed, in 
a previous work we demonstrated differences in the binding 
affinity of various HSPB1 mutants according to the locali-
zation of the mutation in the protein [5]. Subsequently, it 
is possible that each mutation differentially affects HSPB1 
post-translational modification and interaction with molec-
ular targets, resulting in the initiation of different signaling 
cascades. In patients, the various mutations in the HSPB1 
gene result in differences in the severity of the disease, the 
involvement of the sensory and motor functions and the age 
of onset, which may also suggest differences in the patho-
mechanisms involved.
In addition to a deficit in NF axonal transport, increased 
Cdk5 activation and hyperphosphorylation of NFs might as 
well directly affect axonal degeneration in HSPB1 mutants 
as both events have been associated with neurodegenera-
tive diseases [10, 42, 75]. Hyperphosphorylation of NFs 
is an early event observed in many neurodegenerative dis-
orders, such as Alzheimer’s disease (AD), amyotrophic 
lateral sclerosis (ALS), and Parkinson’s disease (PD), for 
which they are used as early biomarkers [13, 14, 24, 44, 
52]. Changes in the phosphorylation status of NFM and 
NFH have been shown to affect axonal transport and axon 
caliber [55], and phosphorylation of the KSP repeats in 
the tail domain of NFH modifies the binding properties of 
the NFs [56]. Hyperphosphorylation of NFs has also been 
linked specifically to axonal damage [45]. While normally 
phosphorylated NFs are found in the distal part of the axon 
[49, 60], hyperphosphorylated NFs are found within pro-
tein accumulations called ‘spheroids’ in the proximal axons 
and neuronal cell body [32, 56]. An increased amount of 
hyperphosphorylated NF bundles could destabilize the 
axonal cytoskeleton and negatively affect the axonal trans-
port of other cargos [31, 36, 43, 68]. It was hypothesized 
that NF aggregates entrap kinesin and dynein motors and 
thus jeopardize overall axonal transport [21, 63]. However, 
we were unable to detect cell body modifications includ-
ing NF aggregates or differences in the distribution of inter-
mediate filaments despite the reported correlation between 
NF hyperphosphorylation, NF–NF interaction and bun-
dles [37, 61]. Although significant, the NF hyperphospho-
rylation seen in our study might not be strong or sustained 
enough to support an increased bundling of NF. The appar-
ent contradiction between the absence of aggregates in this 
study and the aggregates reported in a previous study using 
a similar cellular model [4, 74] can be explained by the 
level of expression of HSPB1. Indeed, the overexpression 
of mutant HSPB1 leads to aggregation of the protein (data 
not shown). While the studies previously cited used cells 
transiently overexpressing HSPB1, we favored a stable cell 
model where the transgene was expressed at a moderate 
level and formation of aggregates was prevented.
Another possibility is that the effect of mutant HSPB1 
on NFs causes cytoskeleton dynamic deficits indirectly, 
through the interaction of NFs to microtubules (MTs). We 
recently showed that some CMT-causing HSPB1 muta-
tions stabilized the MT network and reduced MT dynamics 
by binding more strongly to MTs than wild-type HSPB1 
[6, 7]. On the other hand, NFs have also been shown to 
bind unassembled tubulin, inhibit MT polymerization and 
directly modulate MT assembly in the axon in vivo [12, 30, 
76]. Interestingly, the interaction between NFs and tubulin 
was shown to be lost upon Cdk5-mediated phosphorylation 
of NFH [40]. The Cdk5-dependent hyperphosphorylation 
of NFs could therefore affect NF regulation of MT polym-
erization. Thus, HSPB1 mutations could reduce neuronal 
maintenance by contributing to global transport defects 
affecting the MT network directly and indirectly, through 
deregulation of the level of phospho-NFs. Both MT over-
stabilization [7] and NF hyperphosphorylation could con-
tribute to the destabilization of the cytoskeleton, affect 
axonal transport and compromise the overall integrity of 
the axon.
Patients carrying an HSPB1 mutation are character-
ized by an axonal peripheral neuropathy associated with a 
decrease in the amplitude of the compound muscle action 
potentials, which is consistent with the observed decrease 
in the amount, density and diameter of myelinated nerve 
fibers [11, 38, 39, 62]. Among the few reports of biopsy of 
CMT2F patients, one [11] describes a single patient with 
an HSPB1-S135C mutation showing loss of NFs with 
a simultaneous increase in MT density in the sural nerve 
biopsy, underlining some correlation between these struc-
tures and the pathomechanisms. However, a causal link 
between deficits in the structure, density or function of NF 
and the degeneration of the peripheral axons still needs to 
be demonstrated.
In conclusion, we have shown that mutations in 
HSPB1, a stress protein with ubiquitous functions, affect 
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NF properties, and each of these properties have a direct 
or indirect effect on NF axonal transport. Our present and 
previous works suggest that degeneration of long periph-
eral nerves associated with CMT results from the delete-
rious combination of different pathomechanisms affecting 
axonal transport. Importantly, our study contributes to the 
unraveling of common pathomechanisms linking mutations 
in HSPB1 and NFL to CMT diseases.
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